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The purpose of the article is to demonstrate an equiv-
alence testing software application written under SAS1
Institute software designed for use by pharmaceutical and
other medical research professionals. Besides making
the entire equivalence testing procedure easier and more
efficient, the application “EquivEasy” offers three main
advantages over similar software: a  testing for 3   3
in addition to 2  2 crossover designs, b  familiar SAS
user environment, and c  export flexibility MS Word,
PDF, HTML . Two case studies are presented with report
results provided in tabular and graphical form.
Keywords: equivalence testing, SAS application, cross-
over design, TOST, nonparametric tests, clinical trials.
1. Introduction
The purpose of this paper is to describe a new
SAS software-based statistical application
“EquivEasy”, that has been designed and de-
veloped with the aim of making the actual exe-
cution of equivalence testing procedures easier
for a typical final user  e.g., a researcher in
a pharmaceutical company, etc., while at the
same time ensuring both a high level of statis-
tical competency and access to other powerful
features  e.g., import formats, other statistical
procedures, etc. of the SAS software.
Equivalence testing now represents one of the
most frequently used routine applications in
clinical pharmacokinetic studies.
Although any clinical statistician can easily per-
form an equivalence testing procedure using al-
most any reliable statistical software, less ex-
perienced researchers can benefit from hav-
ing a quick, easy, programming-free, “shrink
wrapped” application for performing both rou-
tine and some of the more demanding equiva-
lence tests.
In some simple situations one can use SAS Ana-
lyst Application’s “equivalence testing” option,
but for more complex situations  e.g., 3   3
crossover design, nonparametric tests, one has
to resort to programming.
Among other software solutions for equivalence
testing the best known is the EquivTest from
Statistical Solutions Ltd., Ireland 10.
The application described in this paper offers
three main advantages as compared to existing
solutions for equivalence testing. They are as
follows:
1 the possibility to performequivalence testing
for 3  3  3 treatments, 3 periods crossover
designs  in addition to 2   2 crossover and
parallel designs,
2 the added flexibility and power of the SAS
environment  the “de facto” standard for sta-
tistical analysis in pharmaceutical industry,
and
3 exporting flexibility  results can be created
in simple listing and various graphics for-
mats, MS word, PDF, and HTML formats.
2. Equivalence Testing
Equivalence studies are different from other
clinical studies in that the desired inference in
equivalence studies, instead of the usual “sig-
nificant difference”, is “practical difference”.
1 SAS is a registered trademark of SAS Institute Inc. in the USA and other countries.
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Therefore, in equivalence studies the null hy-
pothesis tested is “Treatment 1 is NOT equiv-
alent to treatment 2” versus the alternative hy-
pothesis “Treatment 1 is equivalent to treatment
2”.  Note: Treatment 2  T2 is usually denoted




















Table 1. Equivalence vs. superiority trials.
There are, generally speaking, two types of
equivalence studies: clinical equivalence and
bioequivalence studies. Each type has its own
purpose:
In Clinical Equivalence  CE studies treatments
are proclaimed “similar” with respect to clini-
cal outcome  e.g., response rates, BP, survival.
CE can take into account different therapeutic
measures with different mechanisms of action.
In Bioequivalence  BE studies, drugs are “sim-
ilar” with respect to pharmacokinetic charac-
teristics  e.g., AUC, CMAX, TMAX. BE is
limited to drugs with the same mechanism of
action.
Although there are several different approaches
to testing bioequivalence, the most common one
 also recommended by FDA2 11 is based on
equivalence region, and ultimately on confi-
dence sets. The equivalence region E can be
defined as follows:
Let δ denote the difference between treatments
T1 and T2.
Let E be a set of “small” differences.
If δ lies in E  i.e., if δ is “small”, then we say
that T1 and T2 are equivalent.
If δ does not lie in E  i.e., if δ is “large”, then
we say that T1 and T2 differ in a clinically rel-
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Table 3. Typical equivalence regions in clinical
equivalence studies.
Examples of δ and corresponding equivalence
regions in bioequivalence and clinical equiva-
lence studies are given in Table 2 and 3, respec-
tively.
Confidence interval CIα  δ  provides a way to
test if “δ lies in E”. A 100 1α% confidence
interval CIα  δ  for a parameter δ is defined by
ProbfCIα  δ  contains δg  1 α 
The width of the confidence CIα  δ   for a given
δ  depends on the estimate of the standard error
of δ estimate  i.e., standard error of difference in
means or of mean ratio and the type of hypoth-
esis being tested  1 or 2 sided. The estimate of
the standard error, on the other hand, depends on
the experimental design used, statistical model
applied, estimation method, software, etc.
There is a certain amount of controversy and
misunderstanding around the issue of using
100 1  2α% vs. 100 1  α% confidence
interval for testing 2-sided equivalence hypoth-
esis at the level α  see e.g., 1. These and
other issues most relevant to this research topic
will be covered in the following paragraphs.
In this paper we will be focused on the issues re-
lated to bioequivalence studies only  although
most of it also applies to clinical equivalence
studies.
2 Food and Drug Administration, USA
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3. Bioequivalence Testing
Hypotheses that specify only that the popula-
tion means should be “close” are called average
bioequivalence hypotheses. Hypotheses that
state that the whole distribution of bioavailabil-
ities is the same for the test and reference pop-
ulations are called population bioequivalence
hypotheses. Sometimes bioequivalence is de-
fined in terms of parameters that more directly
measure equivalence of response within an indi-
vidual. This is called individual bioequivalence.
Since the FDA currently requires that only the
results of the average bioequivalence tests be
submitted, in this paper we will not consider
either individual or population bioequivalence
tests.
As mentioned, methods for average bioequiva-
lence are based on either the rawdatamodel  un-
transformed or the log-transformed model, and
are derived under the assumptions of normality
or lognormality for between subject  intersub-
ject and within subject  intrasubject variabil-
ities.
To claim bioequivalence in average bioavail-
ability it is commonly required that the ratio
of the two true formulation averages µT µR
be within  80%, 120% limits  or the differ-
ence µT  µR be within 20% of µR, where
T  test formulation, R  reference formu-
lation. However, for the logarithmic trans-
formation of pharmacokinetic responses, the
FDA guidance requests that to claim average
bioequivalence, the ratio of the two formula-
tion averages on the original scale be within
 80%, 125% limit  which corresponds to a
symmetric interval around 0 in the log scale, i.e.,
log 80   log 125. The FDA requires
that the bioequivalence be concluded with 90%
assurance. In pursuit of this goal, several meth-
ods have been proposed in the past two decades.
These methods include:
1 the confidence interval approach,
2 the method of interval hypothesis testing,
3 the bayesian approach, and
4 nonparametric methods.
In this paper, we will discuss the 3 most com-
mon  currently recommended by FDA, and im-
plemented in EquivEasymethods: 1 the “clas-
sical”  shortest confidence interval for µT µR,
2 Schuirmann’s two one sided tests  TOST, 7,
8, and 3 a nonparametric method.
It can be shown that the 90% confidence in-
terval method is equivalent to carrying out two
one sided tests at 5% significance level. Both
of the methods will be discussed and imple-
mented for the raw data model  additive and
then for the log-transformed data model  mul-
tiplicative. However, some caution is advised
with regard to selection of the appropriate test
when the analysis is performed on raw data  see
below.
In the next two paragraphs typical methods for
the analysis of data coming from a crossover
design will be briefly introduced. The analysis
for data from a parallel design is easily found in
standard statistical texts, and will not be dealt
with here.
4. Raw Data Analysis
4.1. Confidence Interval Approach
If the analysis is performed in the original scale,
then the “classic” confidence interval for the ra-
tio µT µR is obtained from the difference con-
dition:
δL  µT  µR  δU  1
using the standard t statistic for µT  µR and
converting it to the  1  2α   100% confi-
dence interval for the ratio µT µR by dividing
the limits for the difference by the least squares
estimate of the reference mean  assuming that
the estimate is the true reference mean µR. Al-
though intuitively appealing and regularly used,
the “classical” procedure may not have the de-
sired level of assurance required by the FDA
in cases where there is a large coefficient of
variation  CV or a large intrasubject variability
 e.g., CV greater than 20%. In other words, the
probability of correctly concluding bioequiva-
lence may not be of the desired level. In this
case  i.e., when CV is greater than 20% it is
suggested that a simulation study  e.g., paramet-
ric bootstrap, see 4 be conducted to evaluate
the finite sample performance of the confidence
limits before a decision on average bioequiv-
alence is made. Yet another alternative in the
case of high variability is to use some other con-
fidence interval method, such as the one based
on Fieller’s theorem  5.
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4.2. TOST
Schuirmann’s  7,8 proposed two one-sided
 TOST procedure suggests taking the conclu-
sion of average bioequivalence at the α level of
significance if, and only if, both H01 and H02
are rejected at a predetermined α level of sig-
nificance:
H01 : µT  µR  δL H02 : µT  µR  δU
Ha1 : µT  µR  δL Ha2 : µT  µR  δU
The tests are performed using two one-sided t
tests as follows:
TL   D δL SE D  tα r  2
TU   D δU SE D  tα r  3
where tα r is the upper 100α percentile of t-
distribution with r degrees of freedom, D is the
estimated difference between test and reference
means, and SE D is the standard error of the
difference.
5. Log-transformed Data Analysis
There are several reasons or rationales for ap-
plying log transformation to AUC and CMAX
data. They are labeled “Clinical”, “Pharma-
cokinetic”, and “Statistical”. The statistical ra-
tionale is that much of pharmacokinetic data is
skewed in original scale and that it appears more
lognormal than normal. Besides, by log trans-
formation, the ratio condition in original scale
changes into a difference condition in the log
scale:
δL  µT µR  δU 
log δL  ηT  ηR  log δU  4
where µi  exp ηi  σ2 2, iT,R and ηi,
σ are parameters of the lognormal distribution.
Here we assume that the log transformed data
are distributed according to the normal distribu-
tion with means µT, µR and a common variance
σ2  i.e., that the original data are distributed ac-
cording to lognormal distribution with param-
eters ηi and δ . As mentioned earlier, recom-
mended limits for logged data are δL  80
and δU  125, which yield symmetric limits
log 80  223 and log 125  223, re-
spectfully, in log scale.
5.1. Confidence Interval Approach
The confidence interval approach in the case of
logged data is straightforward:
CI  D tα rSE D,D  tα rSE D  6
where tα r is the upper 100α percentile of t-
distribution with r degrees of freedom, D is the
estimated difference between test and reference
means, and SE D is the standard error of the
difference. The interval for the ratio of means in
the original scale is obtained by exponentiating
the interval limits  6.
5.2. TOST
In the case of log transformed data, TOST tests
the following two hypotheses:
H01 : ηT  ηR  log δL
H02 : ηT  ηR  log δU
Ha1 : ηT  ηR  log δL
Ha2 : ηT  ηR  log δU
The tests are performed by comparing TL and
TU to the percentiles of the t-distribution as fol-
lows:
TL   D log δL SE D  tα r  7
TU   D log δU SE D  tα r
 8
It can be shown that the 100 1 2α  and not
the 100 1 α confidence interval approach is
operationally identical to TOST performed at α
level.
The width of the confidence interval  and the
decision from TOST depend on  given fixed
δL, δU and the selected bioequivalence method
the estimate of the difference between two drug
means and its standard error. This estimate, on
the other hand, depends on a number of other
things such as:
 experimental design  e.g., crossover vs. par-
allel
 treatment of effects  fixed vs. random
 effects included in model  e.g., with or with-
out carryover effects
 unbalanced data  missing data andor in-
complete designs
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 modeling covariance structure  e.g., differ-
ent variances
 estimationmethod  software, procedure, etc.
5.3. Nonparametric Test
Statistical methods for assessment of bioequiv-
alence are developed under the following as-
sumptions:
Sik  the effect of the ith subject in the kth se-
quence are iid normalwithmean 0 and variance
σ2s  “intersubject” variability,
eijk  the  within subject random error are iid
normal with mean 0 and variances σ2e  “intra-
subject” variability, and
Sik and eijk are mutually independent.
It is important to check these assumptions, and
several approaches based on examining inter-
and intrasubject residuals have been suggested
in the literature. However, they are not rigor-
ous statistical tests for normality and should be
used with caution due to the small number of
subjects usually used in bioequivalence studies
 see 9.
If normality  or lognormality is seriously vi-
olated, TOST  even for log transformed data
is no longer justified. Application EquivEasy
uses a distribution-free approach proposed by
Hauschke D., Steinijans VW, and Diletti E. 6.
The advantage of this approach is its applicabil-
ity even in the case of unequal period effects.
The procedure proposed in 6usesMann-Whit-
ney-Wilcoxon tests and the corresponding distri-
bution-free 100 1 2α% confidence interval,
and the Hodges-Lehman estimator  as a point
estimator for the logged ratio of means. The
approach is specially appealing because it yields
results in the form of 100 12α% confidence
intervals  as with parametric approach, which
are then easily compared to the pre-specified
 bioequivalence range  see Table 5 in para-
graph 6 for an example of the results generated
by the nonparametric option in EquivEasy.
6. EquivEasy Application
Although SAS GLM and MIXED procedures
can be used for “standard” bioequivalence test-
ing  e.g., 90% confidence intervals and TOST,
their use is not straightforward because the tests
results have to be calculated  using appropriate
formulas from SAS procedures outputs. Also,
it is usually necessary to first examine the results
from the model with carryover effects  in case
of crossover design, and then  in the absence
of significant carryover effects from the model
without carryover effects. Furthermore, report-
ing on bioequivalence studies require that some
standard tables, figures and listings  TFL  e.g.,
means, CV, ratios, estimates of inter- and intra-
subject variability, etc. be supplied in addition
to the bioequivalence test s results. These usu-
ally require that appropriate manipulations and
transformations be applied to the data before
TFLs are made.
The purpose of EquivEasy application is:
 to raise the likelihood of proper reporting
on bioequivalence studies  for data from 2
treatments, 2 periods crossover design and
3x3 crossover  Williams design:
 to minimize the errors in report preparation
 increased quality,
 to minimize the maximum time required for
studies  increased efficiency,
 to reduce the need for in-house SAS exper-
tise  i.e., so as to simplify use, and to reduce
training costs,
 tomaximize the uniformity of reporting  stan-
dardization, and
 to minimize additional validation costs by
using pre-validated SAS Institute software
procedures wherever possible.
Using the application is straightforward: appro-
priate selections  such as location of the data, re-
sponse variable name, level names, logoriginal
scale, GLM MIXED nonparametric proce-
dure, withwithout carryover effects, limits,
output format: MS Word HTML PDF, etc.
have to be supplied  as shown in Figure 1 prior
to pushing the “OK” button, which then creates
typical output  tables and graphs in the selected
format.
Data for the first example  3   3 crossover
“Williams” design is taken from 3  Table
10.3.13. The results are generated by select-
ing GLM  parametric procedure, no carryover
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Fig. 1. EquivEasy Application frame.
Fig. 2. “Treatment means by period” plot.
effects, original scale, and  0.80,1.20 bioe-
quivalence limits in the EquivEasy Application
frame. The output was requested in .rtf  MS
Word format. The key results, a graph of treat-
ment means by periods, and a table with 90%
confidence intervals and TOST are shown in
Figure 2 and Table 4, respectively. It can be
shown that the application yields results iden-
tical to the results given in the original Table
10.3.16. in 3  n.b., original table contains
two clerical errors. Incidentally, the results
 both the 90% confidence interval approach and
TOST show that equivalencewith the reference
treatment  R can be concluded only for treat-
ment B.
The second example  2   2 crossover design
is also based on data from 3  Table 3.6.1..
The nonparametric procedure, log scale, and
the usual  .80, 1.25 bioequivalence range for
the logged data were selected to analyze the
second data set. The results for the 90%  HSD
confidence interval based on Mann-Whitney-
Wilcoxon test, a Hodges-Lehman  HSD point
estimate, and an exact confidence coefficient
are given in Table 5. The stated bioequivalence
limits  0.90, 1.25 encompass the 90% HSD
confidence interval  0.94, 1.18. Hence, it is
concluded that the two treatments are equiva-
lent.
Table 5. Nonparametric test results.
7. Summary
Equivalence testing need not consume exces-
sive researcher time and company resources.
Although not simple, the testing procedure can
be made much easier with the aid of “expert
Table 4. 90% parametric confidence intervals and TOST.
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system” software application assistance. The
EquivEasy application  created using SAS In-
stitute softwaremakes equivalence testing both
faster and easier for the pharmaceutical research
professional.
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